Health Care & Life Sciences » Biotechnology | Idera Pharmaceuticals Inc.

Idera Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
29,403.00
41,227.00
60,160.00
109,014.00
112,629.00
71,431
Other Current Assets
874.00
1,203.00
3,082.00
2,030.00
3,992.00
1,376
Total Current Assets
30,277.00
42,430.00
63,242.00
111,044.00
116,621.00
72,807
Net Property, Plant & Equipment
90.00
1,306.00
1,692.00
1,853.00
1,472.00
207
Total Investments and Advances
6,500.00
7,690.00
27,308.00
300.00
300.00
-
Other Assets
-
-
34.00
34.00
24.00
9
Total Assets
36,867.00
51,426.00
92,276.00
113,231.00
118,417.00
73,023
ST Debt & Current Portion LT Debt
-
128.00
261.00
292.00
209.00
Accounts Payable
904.00
2,458.00
1,169.00
556.00
1,334.00
Other Current Liabilities
3,506.00
4,460.00
5,385.00
8,505.00
8,566.00
Total Current Liabilities
4,410.00
7,046.00
6,815.00
9,353.00
10,109.00
Long-Term Debt
-
742.00
501.00
209.00
-
Other Liabilities
5.00
236.00
1,378.00
320.00
613.00
Total Liabilities
4,415.00
8,024.00
8,694.00
9,882.00
10,722.00
Common Equity (Total)
21,460.00
43,402.00
83,582.00
103,349.00
107,695.00
Total Shareholders' Equity
32,452.00
43,402.00
83,582.00
103,349.00
107,695.00
Total Equity
32,452.00
43,402.00
83,582.00
103,349.00
107,695.00
Liabilities & Shareholders' Equity
36,867.00
51,426.00
92,276.00
113,231.00
118,417.00
Preferred Stock (Carrying Value)
10,992.00
-
-
-
-

About Idera Pharmaceuticals

View Profile
Address
505 Eagleview Boulevard
Exton Pennsylvania 19341
United States
Employees -
Website http://www.iderapharma.com
Updated 07/08/2019
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The firm uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C.